Yescarta
Drug
Kite Pharma, Inc.
Total Payments
$67.9M
Transactions
18,298
Doctors
4,265
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $8.9M | 3,595 | 1,527 |
| 2023 | $9.4M | 3,630 | 1,624 |
| 2022 | $10.8M | 2,371 | 490 |
| 2021 | $12.4M | 1,563 | 322 |
| 2020 | $14.7M | 2,472 | 766 |
| 2019 | $4.5M | 2,553 | 689 |
| 2018 | $7.2M | 2,114 | 482 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $59.4M | 5,110 | 87.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.9M | 1,161 | 5.7% |
| Consulting Fee | $2.7M | 769 | 3.9% |
| Travel and Lodging | $1.0M | 2,365 | 1.5% |
| Food and Beverage | $393,066 | 8,711 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $364,040 | 98 | 0.5% |
| Royalty or License | $200,000 | 1 | 0.3% |
| Education | $3,855 | 83 | 0.0% |
Payments by Type
Research
$59.4M
5,110 transactions
General
$8.5M
13,188 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7) | Kite Pharma, Inc. | $13.8M | 0 |
| A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | Kite Pharma, Inc. | $11.1M | 0 |
| A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with Atezolizumab in Subjects with Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA 6) | Kite Pharma, Inc. | $5.8M | 0 |
| A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma | Kite Pharma, Inc. | $3.8M | 0 |
| A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Rituximab or Lenalidomide in Subjects with Refractory Large B-Cell Lymphoma (ZUMA-14) | Kite Pharma, Inc. | $3.7M | 0 |
| A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects with Relapsed/Refractory Large B-cell Lymphoma (ZUMA 9) | Kite Pharma, Inc. | $3.4M | 0 |
| A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) | Kite Pharma, Inc. | $3.3M | 0 |
| A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH PROPHYLACTIC STEROIDS IN SUBJECTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA IN THE OUTPATIENT SETTING | Kite Pharma, Inc. | $3.2M | 0 |
| PA Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL) (Phase 1 Cohort 1&2) (Phase 2 Cohort 3&4 ZUMA 1 - Safety Management Study) | Kite Pharma, Inc. | $2.1M | 0 |
| Kite Master Collaboration Agreement | Kite Pharma, Inc. | $1.8M | 0 |
| A Phase 1-2 Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with 4-1BB DLBCL | Kite Pharma, Inc. | $1.4M | 0 |
| Collaborative: WAVE 1, A Phase I study of anti-CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory primary and secondary central nervous system (CNS) lymphoma | Kite Pharma, Inc. | $1.2M | 0 |
| A Phase 1/2 Open-Label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19) | Kite Pharma, Inc. | $1.1M | 0 |
| A Phase 1-2 Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with 4-1BB DLBCL | Gilead Sciences, Inc. | $1.0M | 0 |
| Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel | Kite Pharma, Inc. | $812,900 | 0 |
| A Phase I study of anti-CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory primary and secondary central nervous system (CNS) lymphoma | Kite Pharma, Inc. | $713,507 | 0 |
| A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Rituximab or Lenalidomide in Subjects with Refractory Large B-Cell Lymphoma (ZUMA-14) | Gilead Sciences, Inc. | $490,851 | 0 |
| A Phase 2 trial of anakinra for the prevention of CAR-T cell mediated neurotoxicity. | Kite Pharma, Inc. | $439,767 | 0 |
| ISR: (Timmerman): IL-1 receptor antagonist (anakinra) to prevent severe immune effector cell-associated neurotoxicity syndrome from axi-cel | Kite Pharma, Inc. | $116,570 | 0 |
| A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA 5) | Gilead Sciences, Inc. | $88,712 | 0 |
Top Doctors Receiving Payments for Yescarta
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Joseph Bailes | — | Frisco, TX | $60.0M | 5,236 |
| , MD | Hematology | Sioux Falls, SD | $432,534 | 326 |
| , MD | Hematology & Oncology | Philadelphia, PA | $377,520 | 351 |
| , M.D., M.S., F.A.C.P | Internal Medicine | Gilbert, AZ | $267,058 | 308 |
| , M.D | Specialist | Sacramento, CA | $219,844 | 130 |
| , MD | Hematology & Oncology | New York, NY | $146,796 | 112 |
| , M.D | Hematology | Hackensack, NJ | $139,120 | 97 |
| Peter Riedell | Hematology & Oncology | Chicago, IL | $132,239 | 120 |
| , M.D | Hematology & Oncology | Durham, NC | $128,898 | 108 |
| , MD | Hematology & Oncology | Denver, CO | $126,185 | 132 |
| , MD PHD | Hematology & Oncology | Seattle, WA | $112,692 | 96 |
| , M.D | Hematology & Oncology | Monroeville, PA | $111,146 | 79 |
| , MD, MPH | Medical Oncology | Salt Lake City, UT | $106,575 | 77 |
| , M.D | Hematology & Oncology | Dallas, TX | $105,112 | 73 |
| , MD | Hematology & Oncology | Hackensack, NJ | $104,142 | 72 |
| , MD | Hematology & Oncology | Dallas, TX | $103,200 | 64 |
| , D.O | Internal Medicine | Omaha, NE | $100,952 | 71 |
| , MD | Medical Oncology | Charlotte, NC | $97,694 | 101 |
| Michael Bishop | Hematology & Oncology | Chicago, IL | $96,894 | 80 |
| , M.D | Hematology & Oncology | Indianapolis, IN | $88,059 | 66 |
| , M.D | Medical Oncology | Nashville, TN | $85,893 | 46 |
| , D.O | Hematology & Oncology | Westwood, KS | $85,126 | 71 |
| , M.D | Internal Medicine | Houston, TX | $82,758 | 61 |
| , MD | Hematology & Oncology | Cincinnati, OH | $82,448 | 45 |
| , M.D | Student in an Organized Health Care Education/Training Program | Dallas, TX | $75,581 | 55 |
Ad
Manufacturing Companies
- Kite Pharma, Inc. $65.6M
- Gilead Sciences, Inc. $2.2M
Product Information
- Type Drug
- Total Payments $67.9M
- Total Doctors 4,265
- Transactions 18,298
About Yescarta
Yescarta is a drug associated with $67.9M in payments to 4,265 healthcare providers, recorded across 18,298 transactions in the CMS Open Payments database. The primary manufacturer is Kite Pharma, Inc..
Payment data is available from 2018 to 2024. In 2024, $8.9M was paid across 3,595 transactions to 1,527 doctors.
The most common payment nature for Yescarta is "Unspecified" ($59.4M, 87.4% of total).
Yescarta is associated with 20 research studies, including "A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7)" ($13.8M).